TNFSF10 and neoplasm: IgBD‐TRAIL exhibits a significantly longer serum half‐life compared to TRAIL, with an increase of 50–60‐fold, as well as a four‐ to seven‐fold increase in tumor uptake and more than 10 times greater in vivo antitumor effect compared to TRAIL [131].